FDA Anti-Infectives Cmte. To Consider Primary S. Aureus Bacteremia Indication
This article was originally published in The Pink Sheet Daily
FDA seeks the committee’s input on whether primary bacteremia due to Staphylococcus aureus should be designated as a separate indication in light of obstacles encountered by sponsors in studying catheter-related blood stream infections.
You may also be interested in...
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.
Companies will share data from the proof-of-concept study, but they do not intend to commercially pursue the use of both drugs in combination.